title: Inhibition of hypertonic saline-induced bronchoconstriction by terfenadine and flurbiprofen. Evidence for the predominant role of histamine.
abstract: We investigated the possible inhibitory effects of terfenadine, a histamine H1-receptor antagonist, and flurbiprofen, a cyclooxygenase inhibitor, on the bronchoconstrictor effect of inhaled 3.6% hypertonic saline in a randomized, double-blind study. Nine mildly asthmatic subjects with a history of exercise-induced asthma took part. This was conducted, first as a dose-response study and, second, as a time-course study. In the dose-response study, the provocative dose of saline-laden air causing a 25% fall in FEV1 was calculated (PD25). Terfenadine (180 mg) and the combination of terfenadine (180 mg) plus flurbiprofen (100 mg) both protected significantly against hypertonic saline challenge, achieving increases in PD25 values by factors of 7.24 and 6.30, respectively. Flurbiprofen (100 mg) also displaced the dose-response to the right, increasing the PD25 by a factor of 1.92, but this protection was significantly less than that afforded by terfenadine. In the time-course studies, a single inhalation of hypertonic saline previously shown to cause at least a 25% fall in FEV1 was administered, and FEV1, was followed for 30 min. Preadministration of terfenadine reduced the mean area under the curve of percentage fall in FEV1-time response by 68.5%, with similar results obtained with the combination of terfenadine and flurbiprofen. We conclude that the bronchoconstriction in asthma provoked by inhaled hypertonic saline is mediated predominantly through the hyperosmolar release of histamine from airway mast cells, with a minor contribution being made by prostanoids.
authors.affiliation: Immunopharmacology Group, Southampton General Hospital, United Kingdom.
authors.forename: J P
authors.initials: JP
authors.lastname: Finnerty
authors.forename: C
authors.initials: C
authors.lastname: Wilmot
authors.forename: S T
authors.initials: ST
authors.lastname: Holgate
mesh_terms: D000328:Adult; D001249:Asthma / Q000503:physiopathology*; D001559:Benzhydryl Compounds / Q000494:pharmacology*; D001980:Bronchi / Q000187:drug effects / Q000503:physiopathology*; D001985:Bronchial Provocation Tests; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005480:Flurbiprofen / Q000494:pharmacology*; D006632:Histamine / Q000502:physiology; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011422:Propionates / Q000494:pharmacology*; D011897:Random Allocation; D012462:Saline Solution, Hypertonic / Q000494:pharmacology*; D012965:Sodium Chloride / Q000494:pharmacology*; D016593:Terfenadine
chemical_list: D001559:Benzhydryl Compounds; D006634:Histamine H1 Antagonists; D011422:Propionates; D012462:Saline Solution, Hypertonic; D012965:Sodium Chloride; D005480:Flurbiprofen; D016593:Terfenadine; D006632:Histamine